ADCT-301 (camidanlumab tesirine, Cami) is an antibody-drug conjugate composed of a monoclonal antibody that binds to CD25 (HuMax®-TAC, licensed from Genmab A/S), conjugated to a toxin (pyrrolobenzodiazepine, PBD) . Once bound to a CD25-expressing cell, Cami is internalized into the cell where enzymes release the PBD-based warhead. In addition to CD25-expressing tumor cells, Cami depletes CD25-positive immune cells in the local tumor environment, which enhances immune-mediated anti-tumor activity.

Pembrolizumab works by inhibiting lymphocytes’ PD-1 receptors, blocking the ligands that would deactivate it and prevent an immune response. This allows the immune system to target and destroy cancer cells, but also blocks a key mechanism preventing the immune system from attacking the body itself.

Dato-DXd (Datopotamab deruxtecan) is an antibody-drug conjugate consisting of a humanized anti-TROP2 IgG1 monoclonal antibody attached to a topoisomerase I inhibitor payload via a stable tetrapeptide-based cleavable linker.

Capivasertib (AZD5363) is a novel, selective ATP-competitive pan-AKT kinase inhibitor that exerts similar activity against the three AKT isoforms, AKT1, AKT2, and AKT3

BT8009 is a Nectin-4 targeting Bicycle toxin conjugate. Bicycle toxin conjugates (BTCs) are a new class of anticancer agents that allow efficient and targeted delivery of toxin payloads into tumours. Nectin-4 is overexpressed in multiple tumour types and is a clinically validated target for selective delivery of cytotoxic payloads.

Nivolumab targets PD-1

BT5528, a BTC targeting EphA2

Olaparib inhibits poly(ADP‐ribose) polymerase, thereby blocking the repair of single‐strand DNA breaks. This results in synthetic lethality in BRCA‐associated cancer cells, which have a dysfunction of another DNA repair pathway – homologous recombination.

TT-702 is a ‘small molecule prodrug’. TT-702 is converted into TT-478, which then targets and blocks the function of the ‘A2B adenosine receptor’. Adenosine signaling via the A2A and A2B receptors is emerging as an important regulatory mechanism of immune responses

Magrolimab, a humanised monoclonal antibody targeting the human cell surface antigen CD47, with potential immunostimulating and antineoplastic activities.

Sacituzumab govitecan is an ADC that consists of a humanised antibody that recognizes Trop-2 covalently attached to the topoisomerase I inhibitor SN-38. The ADC binds to Trop-2–expressing cancer cells, releasing the cytotoxic SN-38.

Niraparib inhibits the role of PARP enzymes, PARP-1 and PARP-2, in DNA repair. By blocking PARP enzymatic activity and increasing the formation of PARP–DNA complexes, niraparib induces DNA damage and cell death.

Atezolizumab is a humanised monoclonal antibody immune checkpoint inhibitor that selectively binds to PD-L1 to stop the interaction between PD-1 and B7. 1 (ie, CD80 receptors). The antibody still allows interaction between PD-L2 and PD-1

Capecitabine is a prodrug that is enzymatically converted to fluorouracil (antimetabolite) in the tumour, where it inhibits DNA synthesis and slows growth of tumour tissue.

Ipatasertib binds to and inhibits the activity of Akt in a non-ATP-competitive manner, which may result in the inhibition of the PI3K/Akt signalling pathway and tumour cell proliferation and the induction of tumour cell apoptosis

SGN-LIV1A targets the zinc transporter LIV-1, expressed by oestrogen receptor-positive breast cancers

Bevacizumab acts by selectively binding circulating VEGF, thereby inhibiting the binding of VEGF to its cell surface receptors. This inhibition leads to a reduction in microvascular growth of tumour blood vessels and thus limits the blood supply to tumour tissues.

Gemcitabine is a nucleoside analog that mediates its antitumour effects by promoting apoptosis of malignant cells undergoing DNA synthesis.

Eribulin is a novel microtubule inhibitor with mitotic and nonmitotic mechanisms of action.

Tocilizumab is a novel monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL-6) to its receptor (IL-6R)

Selicrelumab binds to CD40 on a variety of immune cell types. This triggers the cellular proliferation and activation of antigen-presenting cells (APCs), and activates B cells and T cells, resulting in an enhanced immune response.

INCB106385 is a potent, selective and orally bioavailable dual antagonist of A2A and A2B receptors.

INCMGA00012 is a humanized immunoglobulin G4 (IgG4) monoclonal antibody against human PD-1

ASTX660 (Tolinapant) is an antagonist of the cellular and X-linked inhibitors of apoptosis proteins (cIAP1/2 and XIAP). Inhibitors of apoptosis proteins (IAPs) are frequently overexpressed in tumour cells and contribute to tumour cell survival and chemo-resistance. By inhibiting IAPs, tolinapant promotes cell death.

AZD6738 is an inhibitor of the Serine/Threonine protein kinase Ataxia Telangiectasia and Rad3 related (ATR)

Durvalumab is a human immunoglobulin G1 kappa monoclonal antibody that blocks the interaction of PD-L1 with PD-1 and CD80 (B7. 1) to release the inhibition of immune responses, without inducing antibody-dependent cell-mediated cytotoxicity

KY1044, is a fully human IgG1 anti ICOS antibody designed to stimulate Teffs and to deplete ICOS high Tregs in the tumour microenvironment.

Alpelisib selectively inhibits PIK3 in the PI3K/AKT kinase (or protein kinase B) signalling pathway, thereby inhibiting the activation of the PI3K signalling pathway.

NX-1607 is an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B)

Palbociclib inhibits the phosphorylation of retinoblastoma (Rb) protein, through inhibition of cyclin D-CDK4/6 complex activity, blocking cell cycle progression from G1 into S phase.

Avelumab binds to programmed cell death 1 protein (PD-1) and controls PD-L1 interactions. It also enables the activation of T-cells and the adaptive immune system

Crizotinib is an inhibitor of receptor tyrosine kinases including ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), and Recepteur d’Origine Nantais (RON)

Fulvestrant is an anti-estrogen

Modi-1 is a vaccine composed of a combination of three peptides from two target antigens that are commonly modified in cancer cells.

SEA-TGT is an enhanced human mAb that targets TIGIT and blocks TIGIT’s interaction with CD155 and CD112. T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is an inhibitory immune checkpoint receptor expressed on subsets of T cells and NK cells.

Sasanlimab, a monoclonal antibody (mAb) that blocks the interaction between PD-1 and PD-L1/PD-L2